Ronald Sluyter (R Sluyter)

Scopus Author ID Loop profile UOW Scholars ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 46

Top Venues

International journal of molecular sciences

Purinergic signalling

Dalton transactions (Cambridge, England : 2003)

Immunology and cell biology

University of Sydney (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

University of Sydney

Australia

PHD

Publications

Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Nawal Assadawi, Myles Ferderer, Nicholas Kusi-Appauh, Hai-Bo Yu, Carolyn T Dillon, Ronald Sluyter, Christopher Richardson, Stephen F Ralph
Effect of substituents on the ability of nickel Schiff base complexes with four pendant groups to bind to G-quadruplexes. Dalton transactions (Cambridge, England : 2003) (2024)
Marcela L Chaki Borrás, Rajib Chandra Das, Philip J Barker, Ronald Sluyter, Konstantin Konstantinov
Silica Nanoparticles Decorated with Ceria Quantum Dots Modulate Intra- and Extracellular Reactive Oxygen Species Formation and Selectively Reduce Human A375 Melanoma Cell Proliferation. ACS applied materials & interfaces (2024)
Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Nawal Assadawi, Myles Ferderer, Nicholas Kusi-Appauh, Hai-Bo Yu, Carolyn T Dillon, Ronald Sluyter, Christopher Richardson, Stephen F Ralph
Effect of substituents on the ability of nickel Schiff base complexes with four pendant groups to bind to G-quadruplexes. Dalton transactions (Cambridge, England : 2003) 53 (30) (2024)
Chloe Sligar, Ellie Reilly, Peter Cuthbertson, Kara Lea Vine, Katrina M Bird, Amal Elhage, Stephen I Alexander, Ronald Sluyter, Debbie Watson
Graft-versus-leukaemia immunity is retained following treatment with post-transplant cyclophosphamide alone or combined with tocilizumab in humanised mice. Clinical & translational immunology 13 (3) (2024)
Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Chloe Sligar, Ellie Reilly, Peter Cuthbertson, Kara Lea Vine, Katrina M Bird, Amal Elhage, Stephen I Alexander, Ronald Sluyter, Debbie Watson
Graft-versus-leukaemia immunity is retained following treatment with post-transplant cyclophosphamide alone or combined with tocilizumab in humanised mice. Clinical & translational immunology 13 (3) (2024)
Nawal Assadawi, Myles Ferderer, Nicholas Kusi-Appauh, Hai-Bo Yu, Carolyn T Dillon, Ronald Sluyter, Christopher Richardson, Stephen F Ralph
Effect of substituents on the ability of nickel Schiff base complexes with four pendant groups to bind to G-quadruplexes. Dalton transactions (Cambridge, England : 2003) (2024)
Peter Cuthbertson, Amy Button, Chloe Sligar, Amal Elhage, Kara Lea Vine, Debbie Watson, Ronald Sluyter
Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice. International journal of molecular sciences 25 (3) (2024)
Marcela Laura Chaki Borrás, Georgia Colbran, David R G Mitchell, Philip J Barker, Ronald Sluyter, Konstantin Konstantinov
Multifunctional bismuth oxide (Bi 2 O 3 ) particles: Evidence for selective melanoma therapy. Journal of biomedical materials research. Part A (2023)
Jonathan G Williams, Ronald Sluyter, Martina L Sanderson-Smith
Streptococcus pyogenes emm 98.1 variants activate inflammatory caspases in human neutrophils. Virulence 14 (1) (2023)
Ronald Sluyter
Purinergic Signalling in Physiology and Pathophysiology. International journal of molecular sciences 24 (11) (2023)
Ronald Sluyter, Sahil Adriouch, Stephen J Fuller, Annette Nicke, Reece Andrew Sophocleous, Debbie Watson
Animal Models for the Investigation of P2X7 Receptors. International journal of molecular sciences 24 (9) (2023)
Amal Elhage, Peter Cuthbertson, Chloe Sligar, Debbie Watson, Ronald Sluyter
A Species-Specific Anti-Human P2X7 Monoclonal Antibody Reduces Graft-versus-Host Disease in Humanised Mice. Pharmaceutics 15 (9) (2023)
Chloe Sligar, Peter Cuthbertson, Nicole A Miles, Sam R Adhikary, Amal Elhage, Geoff Zhang, Stephen I Alexander, Ronald Sluyter, Debbie Watson
Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide. Immunology and cell biology (2023)
Reece Andrew Sophocleous, Ronald Sluyter, Carolina Gubert, Srdjan M Vlajkovic, Jennie M E Cederholm
Third meeting of the Australian and New Zealand Purine Club. Purinergic signalling (2023)
Ronald Sluyter, Sahil Adriouch, Stephen J Fuller, Annette Nicke, Reece Andrew Sophocleous, Debbie Watson
Animal Models for the Investigation of P2X7 Receptors. International journal of molecular sciences 24 (9) (2023)
Chloe Sligar, Peter Cuthbertson, Nicole A Miles, Sam R Adhikary, Amal Elhage, Geoff Zhang, Stephen I Alexander, Ronald Sluyter, Debbie Watson
Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide. Immunology and cell biology (2023)
Ross J Turner, Thomas V Guy, Nicholas J Geraghty, Ashleigh Splitt, Debbie Watson, Daniel Brungs, Martin G Carolan, Andrew A Miller, Jeremiah F de Leon, Morteza Aghmesheh, Ronald Sluyter
Low Pretreatment CD4 + :CD8 + T Cell Ratios and CD39 + CD73 + CD19 + B Cell Proportions Are Associated with Improved Relapse-Free Survival in Head and Neck Squamous Cell Carcinoma. International journal of molecular sciences 24 (16) (2023)
Ben J Gu, Stephen J Fuller, Kristen K Skarratt, Leanne Stokes, Malcolm J Wiley, Ronald Sluyter
James Saville Wiley (1936-2022): pioneer of purinergic research in Australia and abroad. Purinergic signalling (2023)
Rachael Bartlett, Diane Ly, Neil R Cashman, Ronald Sluyter, Justin J Yerbury
P2X7 receptor activation mediates superoxide dismutase 1 (SOD1) release from murine NSC-34 motor neurons. Purinergic signalling (2022)
Peter Cuthbertson, Amal Elhage, Dena Al-Rifai, Reece A Sophocleous, Ross J Turner, Ashraf Aboelela, Hiwa Majed, Richard S Bujaroski, Iman Jalilian, Michael J Kelso, Debbie Watson, Benjamin J Buckley, Ronald Sluyter
6-Furopyridine Hexamethylene Amiloride Is a Non-Selective P2X7 Receptor Antagonist. Biomolecules 12 (9) (2022)
Amal Elhage, Chloe Sligar, Peter Cuthbertson, Debbie Watson, Ronald Sluyter
Insights into mechanisms of graft-versus-host disease through humanised mouse models. Bioscience reports 42 (9) (2022)
Peter Cuthbertson, Ronald Sluyter
The P2X7 receptor is a target of p53 and regulates haematopoiesis following radiation-induced genotoxic stress. Purinergic signalling (2022)
Reece Andrew Sophocleous, Lezanne Ooi, Ronald Sluyter
The P2X4 Receptor: Cellular and Molecular Characteristics of a Promising Neuroinflammatory Target. International journal of molecular sciences 23 (10) (2022)
Debbie Watson, Sam R Adhikary, Peter Cuthbertson, Nicholas J Geraghty, Katrina M Bird, Amal Elhage, Chloe Sligar, Ronald Sluyter
Humanized Mouse Model to Study the P2X7 Receptor in Graft-Versus-Host Disease. Methods in molecular biology (Clifton, N.J.) 2510 (2022)
Amal Elhage, Ross J Turner, Peter Cuthbertson, Debbie Watson, Ronald Sluyter
Preparation of the Murine Anti-Human P2X7 Receptor Monoclonal Antibody (Clone L4). Methods in molecular biology (Clifton, N.J.) 2510 (2022)
Alexander Morlando, Marcela Laura Chaki Borrás, Yaser Rehman, Shahnaz Bakand, Philip Barker, Ronald Sluyter, Konstantin Konstantinov
Development of CeO2 nanodot encrusted TiO2 nanoparticles with reduced photocatalytic activity and increased biocompatibility towards a human keratinocyte cell line. Journal of materials chemistry. B 8 (18) (2021)
Peter Cuthbertson, Nicholas J Geraghty, Sam R Adhikary, Katrina M Bird, Stephen J Fuller, Debbie Watson, Ronald Sluyter
Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease. International journal of molecular sciences 22 (15) (2021)
Sam R Adhikary, Peter Cuthbertson, Leigh Nicholson, Katrina M Bird, Chloe Sligar, Min Hu, Philip J O'Connell, Ronald Sluyter, Stephen I Alexander, Debbie Watson
Post-transplant cyclophosphamide limits reactive donor T cells and delays the development of graft-versus-host disease in a humanized mouse model. Immunology 164 (2) (2021)
Nai-Sheng Hsu, Moeava Tehei, Md Shahriar Hossain, Anatoly Rosenfeld, Mohammad J A Shiddiky, Ronald Sluyter, Shi Xue Dou, Yamauchi Yusuke, Konstantin Konstantinov
Oxi-Redox Selective Breast Cancer Treatment: An In Vitro Study of Theranostic In-Based Oxide Nanoparticles for Controlled Generation or Prevention of Oxidative Stress. ACS applied materials & interfaces 13 (2) (2021)
Son Quynh Thai Pham, Nawal Assadawi, Jadon Wells, Reece A Sophocleous, Kimberley J Davis, Hai-Bo Yu, Ronald Sluyter, Carolyn T Dillon, Celine Kelso, Jennifer L Beck, Anthony C Willis, Christopher Richardson, Stephen F Ralph
A new class of quadruplex DNA-binding nickel Schiff base complexes. Dalton transactions (Cambridge, England : 2003) 49 (15) (2020)
Ross J Turner, Nicholas J Geraghty, Jonathan G Williams, Diane Ly, Daniel Brungs, Martin G Carolan, Thomas V Guy, Debbie Watson, Jeremiah F de Leon, Ronald Sluyter
Comparison of peripheral blood mononuclear cell isolation techniques and the impact of cryopreservation on human lymphocytes expressing CD39 and CD73. Purinergic signalling 16 (3) (2020)
Diane Ly, Anjila Dongol, Peter Cuthbertson, Thomas V Guy, Nicholas J Geraghty, Reece Andrew Sophocleous, Lucia Sin, Bradley J Turner, Debbie Watson, Justin J Yerbury, Ronald Sluyter
The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice. Purinergic signalling 16 (1) (2020)
Reece Andrew Sophocleous, Nicole Ashleigh Miles, Lezanne Ooi, Ronald Sluyter
P2Y2 and P2X4 Receptors Mediate Ca2+ Mobilization in DH82 Canine Macrophage Cells. International journal of molecular sciences 21 (22) (2020)
Sam R Adhikary, Peter Cuthbertson, Ross J Turner, Ronald Sluyter, Debbie Watson
A single-nucleotide polymorphism in the human ENTPD1 gene encoding CD39 is associated with worsened graft-versus-host disease in a humanized mouse model. Immunology and cell biology 98 (5) (2020)
Reece Andrew Sophocleous, Tracey Berg, Rocio K Finol-Urdaneta, Vanessa Sluyter, Shikara Keshiya, Lachlan Bell, Stephen J Curtis, Belinda L Curtis, Aine Seavers, Rachael Bartlett, Mark Dowton, Leanne Stokes, Lezanne Ooi, Ronald Sluyter
Pharmacological and genetic characterisation of the canine P2X4 receptor. British journal of pharmacology 177 (12) (2020)
Nicholas J Geraghty, Debbie Watson, Ronald Sluyter
Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease. Immunology and cell biology 97 (6) (2019)
R A Sophocleous, V Sluyter, B L Curtis, S J Curtis, L M Jurak, M Faulks, M Spildrejorde, S Gates, E-J Proctor, A Seavers, D Watson, T Kuit, M Dowton, L Stokes, Ronald Sluyter
Association of a P2RX7 gene missense variant with brachycephalic dog breeds. Animal genetics 51 (1) (2019)
S M Solaiman, Jennifer Algie, Shahnaz Bakand, Ronald Sluyter, Vitor Sencadas, Michael L F Lerch, Xu-Feng Huang, Konstantin Konstantinov, Philip J Barker
Nano-sunscreens - a double-edged sword in protecting consumers from harm: viewing Australian regulatory policies through the lenses of the European Union. Critical reviews in toxicology 49 (2) (2019)
Rachael Bartlett, Leanne Stokes, Stephen J Curtis, Belinda L Curtis, Ronald Sluyter
Probenecid directly impairs activation of the canine P2X7 receptor. Nucleosides, nucleotides & nucleic acids 36 (12) (2017)
Nicholas J Geraghty, Kylie J Mansfield, Stephen J Fuller, Debbie Watson, Ronald Sluyter
The P2X7 receptor is not essential for development of imiquimod-induced psoriasis-like inflammation in mice. Purinergic signalling 13 (4) (2017)
Ronald Sluyter, Kara Lea Vine
N-Alkyl-Substituted Isatins Enhance P2X7 Receptor-Induced Interleukin-1β Release from Murine Macrophages. Mediators of inflammation 2016 (2016)
Aleta Pupovac, Ronald Sluyter
Roles of extracellular nucleotides and P2 receptors in ectodomain shedding. Cellular and molecular life sciences : CMLS 73 (22) (2016)

Ronald Sluyter.css-eqlu8i{font-size:small;padding-left:4px;} (R Sluyter)

Publication Activity (10 Years)

Top Topics

Top Venues

Ronald Sluyter (R Sluyter)